Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
1,NCT04785898,Diagnostic Performance of the ID Now™ COVID-19 Screening Test Versus Simplexa™ COVID-19 Direct Assay,COVID-IDNow,"Active, not recruiting",No Results Available,Covid19,Diagnostic Test: ID Now™ COVID-19 Screening Test,Evaluate the diagnostic performance of the ID Now ™ COVID-19 test carried out by nurses in an emergency department in comparison with the reference PCR test: Simplexa ™ COVID-19 Direct,Groupe Hospitalier Paris Saint Joseph,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,COVID-IDNow,9-Nov-20,22-Dec-20,30-Apr-21,8-Mar-21,,8-Mar-21,"Groupe Hospitalier Paris Saint-Joseph, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT04785898
2,NCT04595136,Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient,COVID-19,Not yet recruiting,No Results Available,SARS-CoV-2 Infection,Drug: Drug COVID19-0001-USR|Drug: normal saline,Change on viral load results from baseline after using COVID19-0001-USR via nebulization,United Medical Specialties,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",COVID19-0001-USR,2-Nov-20,15-Dec-20,29-Jan-21,20-Oct-20,,20-Oct-20,"Cimedical, Barranquilla, Atlantico, Colombia",,https://ClinicalTrials.gov/show/NCT04595136
3,NCT04395482,Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury,TAC-COVID19,Recruiting,No Results Available,covid19,Other: Lung CT scan analysis in COVID-19 patients,A qualitative analysis of parenchymal lung damage induced by COVID-19|A quantitative analysis of parenchymal lung damage induced by COVID-19|The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure.|Automated segmentation of lung scans of patients with COVID-19 and ARDS.|Knowledge of chest CT features in COVID-19 patients and their detail through the use of machine learning and other quantitative techniques.|The ability within which the analysis of artificial intelligence that uses deep learning models can be used to predict clinical outcomes,University of Milano Bicocca,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,TAC-COVID19,7-May-20,15-Jun-21,15-Jun-21,20-May-20,,9-Nov-20,"Ospedale Papa Giovanni XXIII, Bergamo, Italy|Policlinico San Marco-San Donato group, Bergamo, Italy|Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy|ASST di Lecco Ospedale Alessandro Manzoni, Lecco, Italy|ASST Melegnano-Martesana, Ospedale Santa Maria delle Stelle, Melzo, Italy|ASST Monza, Monza, Italy|AUSL Romagna-Ospedale Infermi di Rimini, Rimini, Italy|Istituto per la Sicurezza Sociale-Ospedale della Repubblica di San Marino, San Marino, San Marino",,https://ClinicalTrials.gov/show/NCT04395482
4,NCT04416061,The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic,COVID-19,"Active, not recruiting",No Results Available,COVID,Diagnostic Test: COVID 19 Diagnostic Test,Proportion of asymptomatic subjects|Proportion of subjects with recent contact history|Proportion of subjects with recent travel history,Hong Kong Sanatorium & Hospital,All,"Child, Adult, Older Adult",,2500,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RC-2020-08,25-May-20,31-Jul-20,31-Aug-20,4-Jun-20,,4-Jun-20,"Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT04416061
5,NCT04395924,Maternal-foetal Transmission of SARS-Cov-2,TMF-COVID-19,Recruiting,No Results Available,Maternal Fetal Infection Transmission|COVID-19|SARS-CoV 2,"Diagnostic Test: Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta",COVID-19 by positive PCR in cord blood and / or positive serologies|COVID-19 by positive PCR in amniotic fluid and placenta|New born infected by COVID-19,Centre Hospitalier Régional d'Orléans|Centre de Biophysique Moléculaire - Pr Chantal Pichon|Professeur TOUMI Hechmi,Female,18 Years to 48 Years   (Adult),,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHRO-2020-10,5-May-20,May-21,May-21,20-May-20,,4-Jun-20,"CHR Orléans, Orléans, France",,https://ClinicalTrials.gov/show/NCT04395924
6,NCT04516954,Convalescent Plasma for COVID-19 Patients,CPCP,Enrolling by invitation,No Results Available,COVID 19,Biological: Convalescent COVID 19 Plasma,Evaluate the safety|Change in requirement for mechanical ventilatory support,"Vinmec Research Institute of Stem Cell and Gene Technology|National Institute of Hygiene and Epidemiology, Vietnam|National Hospital for Tropical Diseases, Hanoi, Vietnam|National Institute of Hematology and Blood Transfusion, Vietnam",All,"18 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISC.20.11.1,1-Aug-20,30-Nov-20,30-Dec-20,18-Aug-20,,20-Aug-20,"Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT04516954
7,NCT04476940,COVID-19 Breastfeeding Guideline for African-Americans,COVID-BF,Not yet recruiting,No Results Available,Covid19|Exclusive Breastfeeding,Behavioral: COVID-19 Breastfeeding Support,COVID-19 breastfeeding guidance adherence at birth.|COVID-19 breastfeeding guidance adherence at 1-month postpartum.|COVID-19 breastfeeding guidance adherence at 3-months postpartum.|Exclusive breastfeeding at birth.|Exclusive breastfeeding at 1-month.|Exclusive breastfeeding at 3-months.|COVID_Status|COVID-19 Immunoglobulin G|COVID-19 Immunoglobulin M,Meharry Medical College,Female,18 Years to 45 Years   (Adult),Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,330875,Sep-20,Oct-21,Jun-22,20-Jul-20,,20-Jul-20,"Meharry Medical College, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04476940
8,NCT04634214,The Severity of COVID 19 in Diabetes and Non-diabetes Patients,COVID19,Not yet recruiting,No Results Available,Covid19|Type2 Diabetes,,"Severity of COVID 19 among people with and without diabetes|Number of patients who were in ICU|Number of patients who had tracheal intubation|Number of patients who had respiratory complication|Number of death|Correlation of BMI with complications, tracheal intubation and mortality|Length of hospital stay",India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals,All,"18 Years to 99 Years   (Adult, Older Adult)",,1050,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,IDRFARH015,16-Nov-20,16-Feb-21,16-May-21,18-Nov-20,,18-Nov-20,"Orthomed Hospital, Chennai, Tamil Nadu, India|Medway Hospital, Chennai, Tamil Nadu, India|Venkateswara Hospital, Chennai, Tamil Nadu, India|Dr. Rela Institute & Medical Center, Chennai, Tamil Nadu, India",,https://ClinicalTrials.gov/show/NCT04634214
9,NCT04602884,Early Detection of COVID-19 Using Breath Analysis,COVID-19,Suspended,No Results Available,Covid19,Diagnostic Test: Breath biopsy sampling using the ReCIVA Breath Sampler,Correlation between Volatile Organic Compounds pattern and COVID-19 detection status.|Correlation between Volatile Organic Compounds pattern and time from COVID-19 detection.|Correlation between the set of Volatile Organic Compounds found in breath biopsy and disease intensity.,Scentech Medical Technologies Ltd,All,18 Years to 55 Years   (Adult),Not Applicable,50,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Cov-2-IDF,22-Sep-20,30-Dec-21,30-Dec-21,26-Oct-20,,13-Apr-21,"IDF COVID 19 Isolation Facility, Ashkelon, Israel",,https://ClinicalTrials.gov/show/NCT04602884
10,NCT04384588,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),FALP-COVID,Recruiting,No Results Available,COVID-19 Infection|Cancer Patients|General Population,Biological: Convalescent Plasma from COVID-19 donors,"in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma|safety of the use of convalescent plasma drom COVID 19 donors|Mortality at 30 days, 90 days, 6 months and 1 year|in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports|Number of days of hospitalization in high complexity facilities after convalescent plasma use|Number of days of hospitalization in intensive care unit after convalescent plasma use|Number of days of mechanical ventilatory support in patients after convalescent plasma use|Total number of days of mechanical ventilatory support|Total number of hospitalization days in patients treated with convalescent plasma|Number of hospitalization days in patients after treatment with convalescent plasma|Viral load measuring|Immunological response in treated patients (COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies)|Negativization of COVID 19 load since convalescent plasma use|Negativization of COVID 19 load since hospitalization|Negativization of COVID 19 load since first reported symptoms COVID-19 related|Donor Interferon Gamma profile characterization|Donor Granulocyte Macrophage Colony Stimulating Factor characterization|Donor Tumor Necrosis Factor Alfa characterization|Donor Interleukin -1 beta characterization|Donor Interleukin-2 characterization|Donor Interleukin-4 characterization|Donor Interleukin-6 characterization|Donor Interleukin-8 characterization|Donor Interleukin-10 characterization|Receptor Interferon Gamma profile characterization|Receptor Granulocyte Macrophage Colony Stimulating Factor characterization|receptor Tumor Necrosis Factor Alfa characterization|receptor Interleukin -1 beta characterization|Receptor Interleukin-2 characterization|Receptor Interleukin-4 characterization|Receptor Interleukin-6 characterization|Receptor Interleukin-8 characterization|Receptor Interleukin-10 characterization",Fundacion Arturo Lopez Perez|Confederación de la Producción y del Comercio (CPC)|Bolsa de Santiago,All,"15 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FALP 001-2020,7-Apr-20,6-Apr-21,6-Apr-21,12-May-20,,12-May-20,"Fundacion Arturo Lopez Perez, Providencia, Santiago, Chile",,https://ClinicalTrials.gov/show/NCT04384588
11,NCT04355897,CoVID-19 Plasma in Treatment of COVID-19 Patients,,Recruiting,No Results Available,COVID 19,Biological: Convalescent COVID 19 Plasma,Reduce mortality|Reduce requirement for mechanical ventilation.|Reduce the duration of mechanical ventilation.|Review of treatment related adverse events.,The Christ Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-23,28-Apr-20,Jul-20,Aug-20,21-Apr-20,,20-May-20,"The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04355897
12,NCT04412265,Frailty in Elderly Patients With COVID-19,FRA-COVID,Recruiting,No Results Available,Covid19,Other: Relation between frailty and clinical outcomes in elderly patients with COVID-19.,"Development of a tool to measure frailty|A ""proxy"" variable of the fragility index can be built on the basis of regional administrative databases only.|Give elements to focus the screening policies for COVID19.|Give the prevention of contagion at the elderly population level.",University of Milano Bicocca,All,"18 Years and older   (Adult, Older Adult)",,300,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,FRA-COVID,16-Apr-20,1-Mar-21,1-Mar-21,2-Jun-20,,22-Jan-21,"Dipartimento di Geriatria, Fondazione Poliambulanza, Brescia, Italy|Dipartimento di Medicina e Riabilitazione, Istituto Clinico Ospedale S. Anna, Brescia, Italy|UO Malattie Infettive, Spedali Civili, Brescia, Italy|UOC Medicina I a indirizzo Geriatrico, Spedali Civili, Montichiari, Italy|ASST Monza-Ospedale San Gerardo, Monza, Italy|SCDU Geriatria, AOU Città della Salute e della Scienza - Presidio Molinette, Torino, Italy",,https://ClinicalTrials.gov/show/NCT04412265
13,NCT04659759,"COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes",COVID-PRICE,Recruiting,No Results Available,Covid19,Other: COVID-19 exposure|Biological: COVID-19 vaccine,Maternal COVID-19 serology (IgG and IgM)|Maternal/neonatal IgG and IgM concordance|Maternal COVID serology time/profile following vaccination|Breastmilk Serology|Cytokine|Neonatal cytokine|COVID disease vs vaccination immune response|COVID vaccine in pregnant vs nonpregnant,Thomas Jefferson University|Nemours,Female,"Child, Adult, Older Adult",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20F.1043,17-Nov-20,31-Dec-21,30-Jun-22,9-Dec-20,,5-Mar-21,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04659759
14,NCT04427332,Smell and Taste Disorders in COVID-19 Patients,COVID-19 ORL,Completed,No Results Available,covid19,Other: Investigation of smell and taste disorders,Identification of demographic and clinical factors in covid19 patients.|Description of the disturbances of smell and taste|Description of factors that influence smell and taste,University of Milano Bicocca,All,"18 Years and older   (Adult, Older Adult)",,376,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID-19 ORL,11-Jun-20,16-Oct-20,16-Oct-20,11-Jun-20,,27-Jan-21,"ASST Monza-Ospedale San Gerardo, Monza, Italy",,https://ClinicalTrials.gov/show/NCT04427332
15,NCT04842708,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,COVID-19,Recruiting,No Results Available,Covid19,Diagnostic Test: vaccination against COVID19,Association between breath VOCs and IgG in blood following second vaccination dose.|Association between VOCs profile and participants' clinical or demographic characteristics,Scentech Medical Technologies Ltd,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Cov-2-SMC-V-2020,24-Dec-20,24-Oct-21,24-Oct-21,13-Apr-21,,13-Apr-21,"Shamir Medical Center, Be'er Ya'aqov, Israel",,https://ClinicalTrials.gov/show/NCT04842708
16,NCT04367805,COVID-19 Infection in Patients With Hepatocellular Carcinoma,COVID19-CHIEF,Recruiting,No Results Available,Hepatocellular Carcinoma|COVID-19,Diagnostic Test: nasopharyngeal Covid 19 RT-PCR,Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France,"Centre Hospitalier Universitaire, Amiens|Centre Hospitalier-Universitaire Bondy|University Hospital, Bordeaux|Centre Hospitalier-Universitaire CLICHY|Centre Hospitalier Général CORBEIL-ESSONNE|CHU CRETEIL|University Hospital, Grenoble|University Hospital, Lille|CHU LYON|Poitiers University Hospital|Rennes University Hospital|University Hospital, Rouen|University Hospital, Toulouse|CHU VILLEJUIF|Central Hospital, Nancy, France|Centre Hospitalier Universitaire de Nice|University Hospital, Montpellier",All,"18 Years and older   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,PI2020_843_0042,27-Apr-20,Oct-20,Oct-20,29-Apr-20,,29-Apr-20,"CHU Amiens, Amiens, France",,https://ClinicalTrials.gov/show/NCT04367805
17,NCT04609969,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,COVID-VIRO,Completed,No Results Available,Covid19|SARS-CoV-2 Infection,Diagnostic Test: RT-qPCR test|Diagnostic Test: COVID-VIRO® test,Evaluation of COVID VIRO® diagnostic specificity|Evaluation of COVID VIRO® diagnostic sensitivity|Evaluation of COVID VIRO® diagnostic sensitivity for RT-qPCR Cycle threshold value < or > 28,Centre Hospitalier Régional d'Orléans,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHRO-2020-18,13-Oct-20,17-Oct-20,17-Oct-20,30-Oct-20,,7-Dec-20,"Centre Hospitalier Régional d'Orléans, France, Orléans, France",,https://ClinicalTrials.gov/show/NCT04609969
18,NCT04817553,Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients,IgG4-COVID,Recruiting,No Results Available,IgG4 Related Disease|Covid19,Other: exposure to COVID19,Incidence of COVID-19 in IgG4 patients with pancreatobiliary involvement|Incidence of severe COVID-19 in IgG4 patients with pancreatobiliary involvement|Medications for the underlying IgG4 disease used when patient was diagnosed to have COVID-19|Risk factors associated with COVID-19 infection in IgG4 patients with pancreatobiliary involvement|Incidence of postponement or discontinuation of indicated medical treatment for the underlying IgG4 disease during COVID-19 outbreak,Chinese University of Hong Kong,All,"18 Years and older   (Adult, Older Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,IgG4-COVID,24-Mar-21,Jul-21,Oct-21,26-Mar-21,,26-Mar-21,"Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong",,https://ClinicalTrials.gov/show/NCT04817553
19,NCT04632355,Musculoskeletal Pain in Patients With Covid-19 Who Have Hospital Care,Covid19-Pain,Not yet recruiting,No Results Available,Covid19,Other: Interview,Self-reported Version of the Leeds Assessment of Neuropathic Symptoms and Signs|PainDETEC|EuroQol-5D|The Hospital Anxiety and Depression Scale,Fondazione Don Carlo Gnocchi Onlus,All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Covid19-Pain,1-Dec-20,31-Jul-21,31-Jul-21,17-Nov-20,,19-Nov-20,"Jorge Hugo Villafañe, Milan, Italy",,https://ClinicalTrials.gov/show/NCT04632355
20,NCT04407585,Testing the Accuracy of a Digital Test to Diagnose Covid-19,,Recruiting,No Results Available,Covid-19,Diagnostic Test: Covid-19 swab PCR test,SARS-CoV-2 infection,"King's College London|Zoe Global Limited|Department of Health, United Kingdom",All,"18 Years and older   (Adult, Older Adult)",,1000000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Covid-19 Validation Study,1-Jun-20,10-May-21,10-May-21,29-May-20,,24-Jun-20,"King's College London, London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04407585/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04407585
21,NCT04657510,Femoral frACturEs and COVID-19.,FACE COVID-19,Recruiting,No Results Available,Covid19|Femur Fracture|Fragility Fracture,Other: COVID-19,Survival at discharge day (comparison between the two groups)|Length of stay (comparison between the two groups)|Readmission rate (comparison between the two groups)|Complications rate (comparison between the two groups)|Survival at 30 days after discharge (comparison between the two groups)|Routine lab exams values (comparison between the two groups),Istituto Ortopedico Galeazzi,All,"45 Years and older   (Adult, Older Adult)",,140,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,FACE COVID-19,14-Nov-20,1-Dec-20,31-Dec-20,8-Dec-20,,8-Dec-20,"IRCCS Istituto Ortopedico Galeazzi, Milano, Italy",,https://ClinicalTrials.gov/show/NCT04657510
22,NCT04473170,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,SENTAD-COVID,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19),Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|Drug: COVID-19 standard care,Adverse reactions incidence.|Rate of mortality within 28-days.|Time to clinical improvement on a seven-category ordinal scale.|Assessment of the immune response profile.|Assessment of acute-phase serum markers.,Abu Dhabi Stem Cells Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,146,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT.001.1.0.SENTAD-COVID,4-Apr-20,20-May-20,14-Jul-20,16-Jul-20,,16-Jul-20,"Abu Dhabi Stem Cells Center, Abu Dhabi, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT04473170
23,NCT04497298,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,COVID-19-101,"Active, not recruiting",No Results Available,COVID-19,Biological: Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose|Biological: Two COVID-19 vaccine candidate (TMV-083) administrations - High dose|Biological: One COVID-19 vaccine candidate (TMV-083) administration - High dose|Other: Placebo,"To assess the safety and tolerability of the COVID-19 vaccine following one or two consecutive intramuscular injections in healthy volunteers|To assess induction of SARS-CoV-2 spike protein-binding antibodies upon one or two administrations of the COVID-19 vaccine by means of ELISA up to study day 56|To assess induction of SARS-CoV-2 neutralizing antibodies upon one or two administrations of the COVID-19 vaccine by means of serum neutralization assay up to study day 91|To assess SARS-CoV-2 spike protein-specific, cell-mediated immune responses up to study day 91, induced by one or two doses of vaccine, by means of intracellular staining and flow cytometry.|To assess potential measles virus shedding by means of RT-qPCR of saliva, nasal swab, urine, or blood samples in sentinel groups on day 0 and up to day 42",Institut Pasteur|Themis Bioscience GmbH|Coalition for Epidemic Preparedness Innovations,All,18 Years to 55 Years   (Adult),Phase 1,90,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2020-016|2020-002973-89,10-Aug-20,Jun-21,Jul-21,4-Aug-20,,13-Apr-21,"SGS Life Sciences, Clinical Pharmacology Unit, Antwerp, Belgium|CIC Cochin - Pasteur, Paris, France",,https://ClinicalTrials.gov/show/NCT04497298
24,NCT04549831,Genetic Bases of COVID-19 Clinical Variability,GEN-COVID,Recruiting,No Results Available,COVID-19,Genetic: Massive parallel sequencing of host genome,To identify the genetic determinants of COVID-19 severity|To identify the genetic determinants of COVID-19 clinical trajectories.,"University of Siena|Policlinico San Matteo Pavia Fondazione IRCCS|Ospedale San Donato, Arezzo|Ospedale della Misericordia|Azienda Ospedaliera Ospedale Maggiore di Crema|University of Modena and Reggio Emilia|ASST Fatebenefratelli Sacco|Azienda Ospedaliera di Perugia|Ospedale dell'Angelo, Venezia-Mestre|Azienda Ulss 2 Marca Trevigiana|Cardarelli Hospital|Azienda Ospedaliera dei Colli|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Istituto Giannina Gaslini|Istituti Ospitalieri di Cremona|IRCSS Lazzaro Spallanzani, Roma|ASST Santi Paolo e Carlo|ASST Valtellina e Alto Lario|Azienda USL Toscana Sud Est|ULSS1 Dolomiti, Belluno|ASST Spedali Civili, Brescia|IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Ospedale Luigi Curto, Polla|Istituto Auxologico Italiano|CEINGE Biotecnologie Avanzate, Napoli",All,"18 Years and older   (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,16917,8-Apr-20,8-Apr-21,8-Apr-26,16-Sep-20,,17-Sep-20,"University of Siena, Siena, Italy",,https://ClinicalTrials.gov/show/NCT04549831
25,NCT04706390,Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination,COVID19vac-1,Recruiting,No Results Available,Covid19,Biological: covid-19 vaccine,immune responses|Duration and breadth of B- and T cell responses|Immune responses in healthy people and patient groups at risk,University of Bergen|Haukeland University Hospital,All,"20 Years to 100 Years   (Adult, Older Adult)",,2500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COVID-19vacc-1,12-Jan-21,12-Jan-22,12-Jan-24,12-Jan-21,,12-Jan-21,"University of Bergen, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT04706390
26,NCT04632719,The MentalPlus® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19,MP-COVID,Recruiting,No Results Available,"Cognitive Impairment|Covid19|Cognitive Dysfunction|Depression, Anxiety|Quality of Life",Device: The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19,Assessment of cognitive functions after COVID-19|Rehabilitation of cognitive functions after COVID-19,University of Sao Paulo,All,"8 Years to 88 Years   (Child, Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MentalPlus®,8-Nov-20,29-Dec-20,29-Dec-23,17-Nov-20,,17-Nov-20,"Livia Stocco Sanches Valentin, São Paulo, SP, Brazil|Livia Stocco Sanches Valentin, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04632719
27,NCT04427345,Predictive Factors COVID-19 Patients,MI-COVID,Recruiting,No Results Available,covid19,Other: Predictive factors for clinical response in patients with COVID-19.,"Identify risk factors for intra-hospital mortality.|Identify risk factors to build a prognostic score.|Predictive factors for the hospitalization duration.|Predictive factors for clinical status patients based on ""Ordinal Scale for Clinical Improvement""|Describe the anti-viral therapies used commonly in this emergency in terms of efficacy|Describe the anti-viral therapies used commonly used in this emergency in terms of safety|Monitor the clinical course of the disease in discharged patients.",University of Milano Bicocca,All,"18 Years and older   (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,MI-COVID,30-Apr-20,30-Apr-21,30-Apr-21,11-Jun-20,,9-Nov-20,"ASST Monza-Ospedale San Gerardo, Monza, Italy",,https://ClinicalTrials.gov/show/NCT04427345
28,NCT04424004,MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study,C3PI,"Active, not recruiting",No Results Available,COVID 19,Other: COVID-19 PCR and serology testing,"Estimate the prevalence of COVID-19 infection based on responses to questionnaire items on symptoms and practices using a biweekly electronic survey.|Assess perceptions, concerns, and practices related to the COVID-19 pandemic and mitigation strategies|Estimate of the prevalence of active infection in Cabarrus County.|Estimate of the prevalence of exposure and potential immunity to COVID-19.",Duke University|North Carolina Department of Health and Human Services,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,Pro00105703,9-Jun-20,30-Jun-21,30-Jun-21,9-Jun-20,,17-Nov-20,"Duke CTSI Translational Population Health Office, Kannapolis, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04424004
29,NCT04407494,Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19),COVID-OLFA,Completed,No Results Available,COVID-19,"Biological: Reporting of anosmia, ageusia and other clinical symptoms",Diagnostic values of anosmia and ageusia for COVID-19|Diagnostic values of CODA,"University Hospital, Montpellier",All,"18 Years and older   (Adult, Older Adult)",,809,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL20_0176,1-Mar-20,1-Apr-20,30-Apr-20,29-May-20,,1-Jun-20,"Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04407494
30,NCT04360811,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic",COroFet,Recruiting,No Results Available,Pregnancy,Diagnostic Test: COVID 19 diagnostic test by PCR,number of positive COVID-19 women,"University Hospital, Toulouse",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,3600,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,RC31/20/0123,17-Apr-20,Apr-21,Apr-22,24-Apr-20,,24-Apr-20,"University Hospital of Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04360811
31,NCT04403672,Performance Evaluation of RealDetect™ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus,,Recruiting,No Results Available,High Sensitivity and Specificity (With 95% Confidence Interval) of RealDetect™ COVID-19 RT-PCR Kit,Device: performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection,Performance evaluation of RealDetect™ COVID-19 RT-PCR kit|Reduce the price of RT-PCR based COVID-19 diagnostic test kits.,Bangladesh Medical Research Council (BMRC),All,"5 Years to 65 Years   (Child, Adult, Older Adult)",,120,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,30005052020,18-May-20,24-Jul-20,24-Jul-20,27-May-20,,28-May-20,"Institute of Epidemiology, Disease Control and Research (IEDCR), Mohakhali, Dhaka (For sample collection & sample storage), Institute for Developing Science & Health Initiatives (ideSHi); Mohakhali, Dhaka (For sample analysis, data collection, data analys, Dhaka, Bangladesh",,https://ClinicalTrials.gov/show/NCT04403672
32,NCT04363099,Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.,COVID AMBU 60,Recruiting,No Results Available,Covid-19,Other: observational,clinical description of covid 19 ambulatory cases.|Biological and radiological description of ambulatory cases|Prevalence of positive cases (PCR and/or serological positive),Maison de Sante Pluridisciplinaire de Creil,All,"up to 99 Years   (Child, Adult, Older Adult)",,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Other,2020-A01059-30,1-Mar-20,30-Jun-20,31-Dec-20,27-Apr-20,,27-Apr-20,"Msp de Creil, Creil, France",,https://ClinicalTrials.gov/show/NCT04363099
33,NCT04377425,COVID-19 Prevalence and Cognitive Deficits in Neurological Patients,Neuro-Covid,Withdrawn,No Results Available,"Neurological Diseases or Conditions|Stroke, Acute|Seizure Disorder",Diagnostic Test: COVID-19 swap test PCR,Prevalence of COVID-19 infection in consecutive patients with neurological symptoms|Three months cognitive function of COVID-19 positive patients|Clinical presentation of neurological symptoms in COVID-19 positive patients|Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients|Anosmia in COVID-19 positive patients|Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection|Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients,Aarhus University Hospital,All,"18 Years and older   (Adult, Older Adult)",,0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Neuro-Covid-19,7-May-20,29-Nov-20,30-Jun-22,6-May-20,,3-Sep-20,"Aalborg University Hospital, Aalborg, DK, Denmark|Aarhus University Hospital, Aarhus, DK, Denmark|Regional Hospital West Jutland, Hostebro, Holstebro, DK, Denmark|Regional Hospital Central Jutland, Viborg, Viborg, DK, Denmark",,https://ClinicalTrials.gov/show/NCT04377425
34,NCT04602871,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,COVID-19,Completed,No Results Available,Covid19,Diagnostic Test: Breath Biopsy,Correlation between Volatile Organic Compounds pattern in-breath biopsy and COVID-19 detection.|Correlation between Volatile Organic Compounds pattern and the course of the disease,Scentech Medical Technologies Ltd,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,108,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Cov-2-2020,3-Jul-20,30-Jan-21,30-Jan-21,26-Oct-20,,13-Apr-21,"Soroka Medical Center, Be'er Sheva, Israel|Meir Medical Center, Kfar Saba, Israel",,https://ClinicalTrials.gov/show/NCT04602871
35,NCT04691895,Gastrointestinal Symptoms in COVID-19,,"Active, not recruiting",No Results Available,COVID19 Disease,Other: SARS-CoV2 infection,Prevalence of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease as assessed by GSRS questionnaire|Prognosis of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease|Long term consequences of COVID-19 on gastrointestinal symptoms on the development of post-infection (PI) irritable bowel syndrome (IBS).|long term consequences of COVID-19 on gastrointestinal symptoms on the development of post-infection (PI) dyspepsia.|Identification of risk factors for post-infection gastrointestinal symptom development.,University of Bologna,All,"18 Years to 85 Years   (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,GI-COVID19_01,1-May-20,30-Sep-20,31-Dec-21,31-Dec-20,,5-Jan-21,"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy",,https://ClinicalTrials.gov/show/NCT04691895
36,NCT04645498,COVID-19 and Hereditary Metabolic Diseases,COVID19-MHM,Not yet recruiting,No Results Available,"Covid19|Metabolism, Inborn Errors",,Frequency of MHM imbalance triggered by COVID-19|Number of COVID-19 patients in Gaucher's disease|Number of COVID-19 patients in Urea Cycle Disorder|Severity of COVID-19 infection,"University Hospital, Lille",All,"Child, Adult, Older Adult",,77,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020_52|2020-A02886-33,Jan-21,Jan-23,Jan-23,27-Nov-20,,27-Nov-20,,,https://ClinicalTrials.gov/show/NCT04645498
37,NCT04747821,An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine,Projeto S,"Active, not recruiting",No Results Available,Covid19,Biological: Adsorbed COVID-19 (Inactivated) Vaccine,Incidence of COVID-19 cases after two-doses immunization schedule in clusters in the first quarter of study|Incidence of COVID-19 cases after two-doses immunization schedule in clusters up to one year of study|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization status|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to pre-existing SARS-CoV-2 antibodies|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization coverage|Incidence of hospitalization and death due to COVID-19 after two-doses immunization schedule in clusters|Change in average number of reported COVID-19 cases in the study area in comparison to other neighboring cities|Medically-attended adverse reactions to the study vaccine|Frequency of severe COVID-19 cases|Frequency of adverse events of special interest after immunization|Acceptability of the study vaccine|Adherence to vaccination schedule,Butantan Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 4,27711,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,COV-04-IB,7-Feb-21,May-21,Feb-22,10-Feb-21,,8-Apr-21,"Hospital Estadual de Serrana, Serrana, SP, Brazil",,https://ClinicalTrials.gov/show/NCT04747821
38,NCT04372004,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),CATCH COVID-19,Recruiting,No Results Available,COVID-19,Diagnostic Test: diagnostic tests for COVID-19 infection,detection of viral infection using serology and viral-RNA detection kits|Temporal trend of antibodies in blood,Texas Cardiac Arrhythmia Research Foundation,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,TCAI_CATCH COVID-19,8-May-20,May-21,Jun-21,1-May-20,,11-Aug-20,"Texas Cardiac Arrhythmia Institute, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT04372004
39,NCT04377685,Prediction of Clinical Course in COVID19 Patients,COVID-CTPRED,Recruiting,No Results Available,COVID 19,Other: CT-Scan,diagnostic of COVID disease composite,"Centre Hospitalier Universitaire de Saint Etienne|Institut National des Sciences Appliquées (INSA)|Institut National de la Santé Et de la Recherche Médicale, France|Centre National pour le Recherche Scientifique (CNRS)|Université de Lyon|Université Jean Monnet",All,"18 Years and older   (Adult, Older Adult)",,800,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20CH109|IRBN652020/CHUSTE,1-Mar-20,30-Jun-21,30-Jun-21,6-May-20,,19-Jan-21,"Chu Saint-Etienne, Saint-Étienne, France",,https://ClinicalTrials.gov/show/NCT04377685
40,NCT04717011,Case Series Study to Detect SARS-CoV-2 in Semen of COVID-19 Patients,COVID-19CAST,Recruiting,No Results Available,SARS-CoV-2,Diagnostic Test: PCR test,SARS-CoV-2 semen result,Igenomix,Male,"18 Years to 65 Years   (Adult, Older Adult)",,100,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,IGX1-COV-NA-20-05,Feb-21,Jul-21,Jul-21,20-Jan-21,,10-Feb-21,"Hospital Ruber Internacional, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04717011
41,NCT04412486,COVID-19 Convalescent Plasma (CCP) Transfusion,,Recruiting,No Results Available,COVID-19,Biological: COVID Convalescent Plasma,Change in PaO2/FiO2 after CCP transfusion.|Change in pulse oximetry status after CCP transfusion.|Change in aO2 after CCP transfusion.|Change in respiratory rate after CCP transfusion.|Change in intubation status after CCP transfusion.|Change in Sequential Organ Failure Assessment (SOFA).|Change in 8-point ordinal clinical deterioration scale.|Length of ICU/hospital stay.|Development of plasma transfusion reactions.|Development of immune complex disorders.|Change in anti CoV-2 IgM and IgG levels.,"Gailen D. Marshall Jr., MD PhD|University of Mississippi Medical Center",All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-0137,1-Jun-20,31-May-22,31-May-22,2-Jun-20,,2-Jul-20,"University of Mississippi Medical Center, Jackson, Mississippi, United States",,https://ClinicalTrials.gov/show/NCT04412486
42,NCT04581135,Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19,,Recruiting,No Results Available,COVID-19,Other: COVID-19,Pulmonary follow-up sequelae in patients after COVID-19|Evaluation of risk factors for adverse Outcome after COVID-19|Compare the functional Pulmonary outcome of COVID-19 disease|Compare the radiological Pulmonary outcome of COVID-19 disease|Quality of Life after COVID-19|Physical performance after COVID-19 using Clinical Frailty Scale|Physical performance after COVID-19 using frailty assessment tests|Microbiota and COVID-19,"University Hospital Inselspital, Berne",All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-00799,1-May-20,30-Apr-23,1-Jun-23,9-Oct-20,,9-Oct-20,"St. Claraspital AG - Department of Pulmonary Medicine, Basel, Switzerland|Universtiy Hospital Bern (Inselspital), Department of Pulmonary Medicine - Lead Center, Bern, Switzerland|University and Hospital of Fribourg, Fribourg, Switzerland|Hôpitaux Universitaires de Genève - Service de Pneumologie, Genève, Switzerland|CHUV - Service de Pneumologie, Lausanne, Switzerland|Clinica Moncucco, Lugano, Switzerland|Hôpital du Valais - Service de Pneumologie, Sion, Switzerland|Kantonspital St. Gallen - Klinik für Pneumologie und Schlafmedizin Lungenzentrum, St. Gallen, Switzerland|Universitätsspital Zürich - Klinik für Pneumologie, Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT04581135
43,NCT04387968,"Epidemiological Study of the Covid-19 Presto Test - The ""COVIDOR"" Study",COVIDOR,Recruiting,No Results Available,Coronavirus Infection,Diagnostic Test: Covid-19 presto test,"Study the prevalence of Covid-19 infection, coronavirus (SARS coronavirus-2) in territorial agents in the 3 structures : CCTVL, Loire Valley Region Centre, Orleans Metropolitan city|Determine if there is a relationship between the profession carried out by the agents of the territorial community of Orleans metropolitan city, the Loire Valley Region, the CCTVL and contamination by covid-19","Raphael Serreau|François Rabelais University|Assistance Publique - Hôpitaux de Paris|University Hospital, Paris|Orléans Métropole Service de Médecine Préventive",All,"18 Years to 65 Years   (Adult, Older Adult)",,5000,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,2020-A01414-35,24-Aug-20,24-Mar-21,24-Mar-21,14-May-20,,9-Dec-20,"Unité de Recherche PARADICT-O - Service de Médecine - Orléans Métropole, Orléans, France|Unité de Recherche PARADICT-O - Service de Médecine - Orléans Métropole, Orléans, France",,https://ClinicalTrials.gov/show/NCT04387968
44,NCT04845048,Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine,,Not yet recruiting,No Results Available,Covid19,Biological: Adsorbed COVID-19 (Inactivated) Vaccine,Incidence of adverse events after receiving the Adsorbed COVID-19 (inactivated) Vaccine|Reactogenicity of Adsorbed COVID-19 (inactivated) Vaccine|Safety of Adsorbed COVID-19 (inactivated) Vaccine|safety of Adsorbed COVID-19 (inactivated) Vaccine,Butantan Institute,All,"18 Years and older   (Adult, Older Adult)",,900,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CFV-01-IB,Apr-21,Sep-21,Nov-21,14-Apr-21,,14-Apr-21,"Centro de Saúde Escola da Faculdade de Medicina de Botucatu - Unesp., Botucatu, São Paulo, Brazil|Centro de Saúde Escola da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP-USP) Dr. Joel Domingos Machado., Ribeirão Preto, São Paulo, Brazil|Centro de Referência de Imunobiológicos Especiais. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (CRIEHCFMUSP), São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT04845048
45,NCT04490837,Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID),YCOVID,"Active, not recruiting",No Results Available,Covid-19,Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19,IgG anti-COVID-19|IgM anti-COVID-19|IgA anti-COVID-19|Time of onset symptoms|COVID-19 PCR results|Radiological studies,Corporacion Parc Tauli,All,"18 Years and older   (Adult, Older Adult)",,3500,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2020/587,22-Jun-20,31-Jul-20,30-Sep-20,29-Jul-20,,29-Jul-20,"Parc Tauli University Hospital, Sabadell, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04490837
46,NCT04834908,Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection,PROTECT,Not yet recruiting,No Results Available,SARS-CoV-2 Infection,Biological: Equine COVID-19 Antiserum|Drug: Standard of care,Phase 1 Unexpected serious adverse events|Phase 2 Patients turning COVID-19 negative (RT-PCR negative)|Phase 2 Patients turning COVID-19 negative (RT-PCR Negative)|Phase 1 Patients turning COVID-19 negative (RT-PCR Negative)|Phase 1 Exploratory outcome|Phase 1-Exploratory outcome|Phase 1- Exploratory outcome|Phase 2 Unexpected serious adverse events|Phase 2 Change in WHO clinical progression scale,Bharat Serums and Vaccines Limited,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,160,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BSV_EQ-AB_20_08,May-21,Mar-22,Sep-22,8-Apr-21,,8-Apr-21,,,https://ClinicalTrials.gov/show/NCT04834908
47,NCT04730401,Convalescent Plasma in the Treatment of Covid-19,CP_COVID-19,Recruiting,No Results Available,Covid19,Biological: Convalescent plasma from COVID-19 donors|Biological: Placebo,Safety (SAE)|Rate of intubation|Number of participants initiating systemic corticosteroids|Hospital stay|Mortality|ICU stay|Ventilator days|Severity of respiratory failure|Viral load|Antibody measurements|Thrombotic complication|The rate of participants presenting with coagulopathy disorders|Number of participants with laboratory change|Adverse effects|Convalescent plasma efficacy|Convalescent plasma high vs low titer efficacy|Convalescent plasma efficacy according to donor status,Helsinki University Central Hospital|Finnish Red Cross,All,"18 Years and older   (Adult, Older Adult)",Phase 2,390,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Plasma_Covid-19,27-Jan-21,31-Aug-21,31-Dec-21,29-Jan-21,,8-Mar-21,"Helsinki University Central Hospital, Helsinki, Uusimaa, Finland",,https://ClinicalTrials.gov/show/NCT04730401
48,NCT04799444,LATE-COVID/LATE-COVID-Kids - Observational Study in Children and Adults,LATE-COVID,Recruiting,No Results Available,Covid19,,Number of participants with severe post-COVID-19 complications|Factors related to the severity of post-COVID-19 complications,Polish Mother Memorial Hospital Research Institute,All,"Child, Adult, Older Adult",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,LATE-COVID,1-Oct-20,30-Jun-22,30-Jun-22,16-Mar-21,,16-Mar-21,"Polish Mother Memorial Research Institute (PMMHRI) in Lodz, Poland, Lodz, Poland",,https://ClinicalTrials.gov/show/NCT04799444
49,NCT04425707,Ivermectin In Treatment of COVID 19 Patients,,Recruiting,No Results Available,Covid19,Drug: Ivermectin,to evaluate the role of Ivermectin as a line of treatment for COVID 19|To asses the rate of viral clearance in comparison to other treatment protocols.,"Ministry of Health and Population, Egypt",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-2020/3,9-Jun-20,1-Jul-20,1-Sep-20,11-Jun-20,,11-Jun-20,"isolation and referal hospitals for COVID 19 patients, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT04425707
50,NCT04356560,COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department,,Enrolling by invitation,No Results Available,COVID-19,"Diagnostic Test: COVID-19 test, polymerase chain reaction for SARS-CoV-2",Incidence of healthcare workers with SARS-CoV-2|Incidence of ENT patients with SARS-CoV-2|Development of SARS-CoV-2 antibodies among healthcare workers|Sensitivity and specificity of a COVID-19 screening symptom questionnaire among healthcare workers|SARS CoV-2 and bacterial super infections in upper respiratory airways,"Rigshospitalet, Denmark",All,"Child, Adult, Older Adult",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,DT P-2020-353,23-Mar-20,30-Sep-20,31-Dec-20,22-Apr-20,,24-Apr-20,"Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT04356560
